Forfivo Tablet, Film Coated, Extended Release
NDC Package 24979-247-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Forfivo (bupropion hydrochloride) tablets is a medication used to treat depression. This formulation utilizes a tablet, film coated, extended release delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 24979-247 and is authorized under FDA application NDA022497.

Identification & Billing

NDC Package Code
24979-247-06
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
24979024706
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 1232585 - buPROPion HCl 450 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1232585 - 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet
  • RxCUI: 1232585 - bupropion hydrochloride 450 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 1232591 - Forfivo XL 450 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1232591 - 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet [Forfivo]

Clinical Specifications

Proprietary Name
Forfivo XL
Non-Proprietary Name
Bupropion Hydrochloride
Substance Name
Bupropion Hydrochloride
Dosage Form
Tablet, Film Coated, Extended Release - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
This medication is used to treat depression. It may also be used to prevent seasonal affective disorder (SAD), a type of depression that occurs each year at the same time (for example, during winter). This medication can improve your mood and feelings of well-being. It may work by restoring the balance of certain natural substances (dopamine, norepinephrine) in the brain.

Regulatory & Marketing

Labeler Name
Upsher-smith Laboratories, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA022497
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-15-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24979-247-06 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Forfivo XL, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This tablet, film coated, extended release is formulated for oral use and contains bupropion hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on December 15, 2023. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat depression. It may also be used to prevent seasonal affective disorder (SAD), a type of depression that occurs each year at the same time (for example, during winter). This medication can improve your mood and feelings of well-being. It may work by restoring the balance of certain natural substances (dopamine, norepinephrine) in the brain.

How is this Upsher-smith Laboratories, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24979024706. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24979-247-06
11-Digit CMS (5-4-2)
24979-0247-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.